Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations

International Journal of Antimicrobial Agents

Volumn 51, Issue 5, 2018, Pages 670-677

  Wi, Yu Mi ^a,b   Greenwood Quaintance, Kerryl E ^a   Brinkman, Cassandra L ^a   Lee, Jean Y H ^c   Howden, Benjamin P ^c   Patel, Robin ^a  

^a MAYO CLINIC   (United States)

^b Sungkyunkwan University   (South Korea)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Fitness cost; rpoB mutation; Staphylococcus epidermidis

Indexed keywords

ASPARAGINE; ASPARTIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; LYSINE; PHENYLALANINE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; SERINE; TYROSINE; BACTERIAL PROTEIN; DNA DIRECTED RNA POLYMERASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM COLONY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG DETERMINATION; DRUG EFFECT; GENE MUTATION; GENE SEQUENCE; GROWTH RATE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR TYPING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE; STAPHYLOCOCCUS EPIDERMIDIS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

BACTERIAL PROTEINS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; RIFAMPIN; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 85044927973     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.12.019     Document Type: Article

References (37)

1. Zimmerli, W., Trampuz, A., Ochsner, P.E., Prosthetic-joint infections. N Engl J Med 351 (2004), 1645–1654.
2. Becker, K., Heilmann, C., Peters, G., Coagulase-negative staphylococci. Clin Microbiol Rev 27 (2014), 870–926.
3. Widerström, M., Wiström, J., Sjöstedt, A., Monsen, T., Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus. Eur J Clin Microbiol Infect Dis 31 (2012), 7–20.
4. Patel, R., Biofilms and antimicrobial resistance. Clin Orthop Relat Res, 2005, 41–47.
5. Donlan, R.M., Costerton, J.W., Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15 (2002), 167–193.
6. Trampuz, A., Widmer, A.F., Infections associated with orthopedic implants. Curr Opin Infect Dis 19 (2006), 349–356.
7. Costerton, J.W., Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res, 2005, 7–11.
8. Crowe, J.F., Sculco, T.P., Kahn, B., Revision total hip arthroplasty: hospital cost and reimbursement analysis. Clin Orthop Relat Res, 2003, 175–182.
9. Zimmerli, W., Widmer, A.F., Blatter, M., Frei, R., Ochsner, P.E., Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279 (1998), 1537–1541.
10. Campbell, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104 (2001), 901–912.
11. Adekambi, T., Drancourt, M., Raoult, D., The rpoB gene as a tool for clinical microbiologists. Trends Microbiol 17 (2009), 37–45.
12. Tupin, A., Gualtieri, M., Roquet-Banères, F., Morichaud, Z., Brodolin, K., Leonetti, J.P., Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. Int J Antimicrob Agents 35 (2010), 519–523.
13. O'Neill, A.J., Huovinen, T., Fishwick, C.W., Chopra, I., Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 50 (2006), 298–309.
14. Clinical and Laboratory Standards Institute, M100-S27: performance standards for antimicrobial suceptibility testing; twenty-seventh informational supplement. 2017, CLSI, Wayne, PA.
15. Brinkman, C.L., Tyner, H.L., Schmidt-Malan, S.M., Mandrekar, J.N., Patel, R., Causes and implications of the disappearance of rifampin resistance in a rat model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob Agents Chemother 59 (2015), 4481–4488.
16. Lee, J.Y., Park, Y.K., Chung, E.S., Na, I.Y., Ko, K.S., Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa. Sci Rep, 6, 2016, 25543.
17. Furustrand Tafin, U., Trampuz, A., Corvec, S., In vitro emergence of rifampicin resistance in Propionibacterium acnes and molecular characterization of mutations in the rpoB gene. J Antimicrob Chemother 68 (2013), 523–528.
18. Aubry-Damon, H., Soussy, C.J., Courvalin, P., Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 42 (1998), 2590–2594.
19. Lee, J.Y.H., Monk, I.R., Pidot, S.J., Singh, S., Chua, K.Y.L., Seemann, T., et al. Functional analysis of the first complete genome sequence of a multidrug resistant sequence type 2 Staphylococcus epidermidis. Microb Genom, 2, 2016 e000077.
20. Bankevich, A., Nurk, S., Antipov, D., Gurevich, A.A., Dvorkin, M., Kulikov, A.S., et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19 (2012), 455–477.
21. Salipante, S.J., SenGupta, D.J., Cummings, L.A., Land, T.A., Hoogestraat, D.R., Cookson, B.T., Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology. J Clin Microbiol 53 (2015), 1072–1079.
22. Gaupp, R., Lei, S., Reed, J.M., Peisker, H., Boyle-Vavra, S., Bayer, A.S., et al. Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype. Antimicrob Agents Chemother 59 (2015), 4226–4238.
23. Wichelhaus, T.A., Boddinghaus, B., Besier, S., Schäfer, V., Brade, V., Ludwig, A., Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002), 3381–3385.
24. Floss, H.G., Yu, T.W., Rifamycin—mode of action, resistance, and biosynthesis. Chem Rev 105 (2005), 621–632.
25. Hellmark, B., Unemo, M., Nilsdotter-Augustinsson, A., Söderquist, B., Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect 15 (2009), 238–244.
26. Cui, L., Isii, T., Fukuda, M., Ochiai, T., Neoh, H.M., Camargo, I.L., et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 54 (2010), 5222–5233.
27. Katayama, Y., Sekine, M., Hishinuma, T., Aiba, Y., Hiramatsu, K., Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus phenotype of strain Mu50 in vancomycin-susceptible S. aureus. Antimicrob Agents Chemother 60 (2016), 3730–3742.
28. Matsuo, M., Hishinuma, T., Katayama, Y., Cui, L., Kapi, M., Hiramatsu, K., Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother 55 (2011), 4188–4195.
29. Wichelhaus, T.A., Schäfer, V., Brade, V., Böddinghaus, B., Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 43 (1999), 2813–2816.
30. Andersson, D.I., Levin, B.R., The biological cost of antibiotic resistance. Curr Opin Microbiol 2 (1999), 489–493.
31. Björkman, J., Andersson, D.I., The cost of antibiotic resistance from a bacterial perspective. Drug Resist Updat 3 (2000), 237–245.
32. Levin, B.R., Lipsitch, M., Perrot, V., Schrag, S., Antia, R., Simonsen, L., et al. The population genetics of antibiotic resistance. Clin Infect Dis 24:Suppl. 1 (1997), S9–16.
33. Gagneux, S., Long, C.D., Small, P.M., Van, T., Schoolnik, G.K., Bohannan, B.J., The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312 (2006), 1944–1946.
34. Böttger, E.C., Springer, B., Pletschette, M., Sander, P., Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 4 (1998), 1343–1344.
35. Vergidis, P., Schmidt-Malan, S.M., Mandrekar, J.N., Steckelberg, J.M., Patel, R., Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant Staphylococcus aureus osteomyelitis. J Infect 70 (2015), 609–615.
36. Aiba, Y., Katayama, Y., Hishinuma, T., Murakami-Kuroda, H., Cui, L., Hiramatsu, K., Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-homogeneous conversion of β-lactam resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57 (2013), 4861–4871.
37. Enne, V.I., Delsol, A.A., Roe, J.M., Bennett, P.M., Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother 53 (2004), 203–207.